Correction to “Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1–4 trials”

Rubino, D, Bjorner, JB, Rathor, N, Sharma, AM, Huth, Smith L, Wharton, S, Wadden, T, Zeuthen, N, Kolotkin, RL. Diabetes, Obesity and Metabolism 2024; 26(7): 2945–2955. DOI: 10.1111/dom.15620

In the abstract, the p-value for the difference in achievement of the MWPC threshold for SF-36v2 Physical Functioning was reported as p = 0.00001; the correct value is p = 0.0005 (as shown in Figure 2).

In Table 1, the SD of the age of participants in STEP 4 was reported as 11.9; the correct value is 11.7. The waist circumference of participants in STEP 1 was reported as 114 cm; the correct value is 114.7 cm. The number and proportion of participants in STEP 1 with prediabetes were reported as 855 and 43.6%; the correct values are 856 and 43.7%.

In section 3.2.2, the proportion of participants receiving placebo in STEP 1 who reached the ≥4.5 point MWPC threshold was reported as 13.0%; the correct value is 12.9%. The ETD for STEP 4 was reported as 5.0; the correct value is 4.9.

In section 3.2.3, the Figure S6 p-values were summarized as p < 0.001; the correct summary is p < 0.01.

In Figure 1B, some error bars did not align with the 95% CIs shown in the column on the right. In Figure 1A and 1B, there were some minor rounding errors in a small number of the data points in the columns.

In Figure 2B, the upper 95% CIs for the STEP 1 and STEP 2 SF-36v2 ETDs were reported as 20.9 and 21.3; the correct values are 20.8 and 21.2.

In Table S4, the ETD for proportion of participants achieving MWPC for Psychosocial score for STEP 2 was reported as 5.4; the correct value is 5.3. The upper 95% CI for Physical score for STEP 2 was reported as 11.2; the correct value is 11.3.

In Figure S6B, the number participants in STEP 2 with <5% weight loss was reported as 582; the correct value is 542.

In Figure S7B, the upper 95% CI for the STEP 1 full trial population ETD was reported as 20.9; the correct value is 20.8. The proportion of participants in STEP 2 with poor PF at baseline in the semaglutide group achieving MWPC was reported as 53.6%; the correct value is 53.5%. The proportions of participants in the full trial population achieving this threshold were reported as 18.0% for the semaglutide group and 6.6% for the placebo group; the correct values are 41.0% and 27.3%. The upper 95% CI for the corresponding ETD was reported as 21.3; the correct value is 21.2. The p-value for this ETD was reported as p = 0.0061; the correct value is p = 0.0005.

In Figure S9B, the baseline value for ‘Unable to stand comfortably’ was reported as 2.11; the correct value is 2.06. The baseline value for ‘Unable to walk far/quickly’ was reported as 2.57; the correct value is 2.37.

We apologize for these errors.

The online version of the article has been corrected, and the supporting information file has been corrected and resupplied.